Catalin Toma
Interventional Cardiology · Pittsburgh, PANPI 1356441497
Payments from drug & device makers
Across 763 payments — averaging $683.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$239K
- Abbott$87K
- Philips North America LLC$62K
- Shockwave Medical, Inc$44K
- Edwards Lifesciences$37K
- Stryker$20K
- plus $33K from 23 others
What the payments were for
- Consulting fees$4,8004%
- Speaking & faculty fees$9,1738%
- Travel & lodging$85,47471%
- Food & beverage$20,48417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 213 | $238,985 |
| Abbott | 166 | $87,178 |
| Philips North America LLC | 23 | $62,429 |
| Shockwave Medical, Inc | 34 | $43,549 |
| Edwards Lifesciences | 24 | $36,956 |
| Stryker | 9 | $19,800 |
| Medtronic(2 entities) | 165 | $16,670 |
| Neptune Medical Inc. | 2 | $5,280 |
| Boston Scientific | 43 | $4,051 |
| Ancora Heart, Inc. | 9 | $2,990 |
| Abiomed | 23 | $2,237 |
| Livanova USA, Inc. | 4 | $194 |
| Amgen | 8 | $175 |
| Recor Medical Inc | 1 | $162 |
| Cardiva Medical, Inc. | 6 | $135 |
| E.r. Squibb & Sons, L.L.C. | 7 | $131 |
| Terumo Medical Corporation | 1 | $129 |
| W. L. Gore & Associates, Inc. | 3 | $128 |
| Teleflex LLC | 2 | $92 |
| Vifor Pharma, Inc. | 6 | $88 |
| Cardiovascular Systems Inc. | 4 | $81 |
| Boehringer Ingelheim | 2 | $59 |
| Asahi Intecc USA, Inc. | 1 | $49 |
| Heartflow, Inc. | 2 | $39 |
| Biotronik Inc. | 1 | $37 |
| Endotronix, Inc. | 1 | $28 |
| Merck | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$68,862
- FLOWTRIEVER CATHETER, S$50,588
- COREVALVE EVOLUT R$8,057
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$4,114
- RESOLUTE ONYX$3,301
- FlowTriever$3,260
- ClotTriever$3,260
- AccuCinch$2,874
- Xience V coronary stent system$1,904
- Impella$1,543
- US Und$1,200
- VersaCross Access Solution$720
- (6361) Core Mobile$600
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$560
- (5027) Intact Vascular Und$524
- PORTICO$474
- Micra$448
- GENERAL - THERAPIES$395
- WATCHMAN Access System$320
- SYNERGY$318
How this compares
$521,710 in reported general payments places this provider in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $183,450 |
| JardianceEmpagliflozin | 158 | $179,080 |
| EntrestoSacubitril/Valsartan | 125 | $146,322 |
| Repatha SureclickEvolocumab | 122 | $112,679 |
| XareltoRivaroxaban | 36 | $35,354 |
| FarxigaDapagliflozin Propanediol | 18 | $27,401 |
| BrilintaTicagrelor | 36 | $23,114 |
| Praluent PenAlirocumab | 24 | $17,856 |
| Metoprolol Succinate | 354 | $7,050 |
| Atorvastatin Calcium | 306 | $4,595 |
| ClopidogrelClopidogrel Bisulfate | 279 | $4,010 |
| Rosuvastatin Calcium | 214 | $3,966 |
| Ezetimibe | 93 | $2,647 |
| Ranolazine ErRanolazine | 22 | $2,595 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 149 | $2,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $183,450187 claims |
| Boehringer IngelheimJardiance | $59 | $179,080158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Pittsburgh
- Ramzi KhalilPittsburgh$1.6M
- David LasordaPittsburgh$1.1M
- Anson SmithPittsburgh$518K
- Saad TabbaraPittsburgh$355K
- Suresh MulukutlaPittsburgh$260K
- Ryan ZuzekPittsburgh$152K
- Dustin KlinerPittsburgh$93K
- Mithun ChakravarthyPittsburgh$79K
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.